Testosterone Buccal: How It Works, Doses, and How It Compares to Other TRT Forms

What Is Testosterone Buccal and How Does It Work?

Testosterone buccal is a small, bioadhesive tablet pressed against the upper gum above the incisor. It releases testosterone continuously through the buccal mucosa, sending the hormone directly into systemic circulation without passing through the gastrointestinal tract or liver. That route matters because oral testosterone tablets swallowed whole undergo extensive first-pass hepatic metabolism, which historically raised concerns about liver toxicity and produced erratic serum levels.

The Striant system uses a patented hydroxypropyl cellulose polymer that softens when moistened and adheres firmly to the gum surface. Testosterone diffuses through the mucosal epithelium and enters the superior labial veins, bypassing hepatic first-pass entirely. The FDA approved Striant in 2003 based on data showing the system raised mean serum total testosterone into the normal physiologic range (300, 1 to 000 ng/dL) in hypogonadal men [1].

A 2004 study by Dobs et al. (N=98) published in the Journal of Clinical Endocrinology and Metabolism reported that 30 mg buccal testosterone applied twice daily produced a mean steady-state total testosterone of 548 ng/dL, with 71% of men achieving levels within the normal range throughout the 12-month observation period [2]. Serum levels stabilized within approximately 12 hours of the first application, making this one of the faster-acting non-injectable options available.

Because each tablet dissolves over roughly 12 hours, serum testosterone follows a relatively flat pharmacokinetic profile compared with, say, testosterone propionate, which produces sharp peaks and troughs. The Endocrine Society's 2018 clinical practice guideline on male hypogonadism states that testosterone formulations should be chosen based on the patient's preferences, willingness to self-administer injections, skin condition, insurance coverage, and desired pharmacokinetic profile [3].

Dosing Protocol and Administration Technique

The standard dose is one 30 mg tablet applied every 12 hours. Most clinicians target trough serum testosterone at 350 to 550 ng/dL and check a 12-hour post-application level (which represents the trough) at weeks 4 and 12 of therapy [1].

Correct placement is essential. The tablet is pressed firmly with a finger against the upper gum for 30 seconds. It should not be chewed, swallowed, or placed on the lower gum. Eating, drinking, and brushing teeth are permitted; the tablet stays in place during normal oral activity in the majority of users, though vigorous mouth rinsing may dislodge it prematurely.

If a tablet falls out within 4 hours of application, the patient should apply a replacement and maintain the original 12-hour schedule [1]. If it falls out after 4 hours, no replacement is needed; the next dose is taken at the regularly scheduled time.

Serum monitoring follows a practical schedule. Total testosterone is drawn at steady state (after at least 1 week of consistent use), ideally 4 to 12 hours after application to capture a mid-to-trough level. The American Urological Association's 2018 testosterone deficiency guidelines recommend monitoring serum testosterone, hematocrit, and prostate-specific antigen (PSA) at 3 and 6 months after initiation, then annually [4].

A hematocrit above 54% should prompt dose reduction or a temporary treatment pause, because erythrocytosis increases thrombotic risk regardless of the delivery route used [4].

Side Effects and Safety Profile

Gum-related adverse events are the most distinctive risk with buccal testosterone. In the Dobs 2004 trial, approximately 16% of men reported mild-to-moderate gum or mouth irritation, and 2% discontinued because of it [2]. Tender gums, altered taste, and minor gum recession have been reported in post-marketing surveillance data reviewed in the Striant prescribing information [1].

Systemic side effects mirror those of other testosterone formulations. Erythrocytosis (hematocrit above 50%) occurred in roughly 5% of subjects in the 12-month Dobs trial [2]. A 2010 meta-analysis in the Journal of Clinical Endocrinology and Metabolism (N=2,036 men across 51 trials) found that testosterone therapy approximately doubled the odds of erythrocytosis compared with placebo (odds ratio 3.67 to 95% CI 1.82, 7.51) [5]. That risk is not unique to the buccal route; it applies across all formulations.

Cardiovascular considerations require attention. The FDA added a class label warning in 2015 requiring all testosterone products to carry information about the risk of venous thromboembolism and a warning that cardiovascular risk had not been fully characterized at that time [6]. The TRAVERSE trial (N=5,204, 2023) subsequently provided more reassurance: testosterone replacement in men with hypogonadism and elevated cardiovascular risk did not increase major adverse cardiovascular events compared with placebo over a median 33-month follow-up [7].

Suppression of spermatogenesis occurs with buccal testosterone as with every exogenous testosterone product. Men who want to preserve fertility should discuss alternatives such as clomiphene citrate or human chorionic gonadotropin (hCG) co-administration with their physician before starting any testosterone therapy [3].

Testosterone Buccal vs. Testosterone Cypionate

Testosterone cypionate is the most prescribed TRT formulation in the United States. It is a long-chain ester (half-life approximately 8 days) dissolved in cottonseed oil and injected intramuscularly or subcutaneously, typically at doses of 50 to 200 mg every 7 to 14 days [8].

The pharmacokinetic difference between the two is pronounced. Cypionate produces a supraphysiologic peak (often 1,000, 1 to 500 ng/dL) in the first 24 to 72 hours after injection, followed by a slow decline toward trough. Buccal testosterone produces a flatter curve, with peak-to-trough variation generally within 200 to 300 ng/dL across a 24-hour dosing interval [2]. Men who experience mood variability, energy crashes, or libido fluctuations tied to injection timing may find the buccal system's steadier profile preferable.

Cost and convenience trade in opposite directions. A 30-day supply of testosterone cypionate 200 mg/mL (10 mL vial) commonly costs $30, $60 at compounding pharmacies; Striant's branded pricing has been substantially higher, though generic buccal testosterone is available. Cypionate requires needle and syringe supplies and disposal. Buccal tablets require neither.

The 2018 Endocrine Society guideline notes that no formulation of testosterone has proven superior in terms of symptom relief, and that selection should account for patient preference and route tolerability [3].

Testosterone Buccal vs. Testosterone Enanthate

Testosterone enanthate carries a half-life of approximately 4.5 days, slightly shorter than cypionate, and is typically dosed at 75 to 100 mg every 5 to 7 days when used for TRT (rather than the older every-2-week protocol, which produces wider troughs) [9]. It is the dominant long-acting injectable in Europe and shares the same clinical evidence base as cypionate for symptomatic hypogonadism.

A 1999 randomized crossover trial by Meikle et al. (N=34) comparing testosterone enanthate injections with testosterone patches found that injectable testosterone produced serum levels that oscillated from above 1 to 200 ng/dL at peak to below 300 ng/dL at trough on a 2-week schedule [9]. Those wide swings are the central pharmacokinetic argument in favor of non-injectable forms, including buccal delivery.

For men who already self-inject and are well-controlled on enanthate, switching to the buccal system adds twice-daily adherence demands. Each approach has a distinct compliance burden. Buccal tablets demand twice-daily consistency; injectable esters demand less frequent but more technically involved administration.

Testosterone Buccal vs. Testosterone Propionate

Testosterone propionate has a very short half-life of roughly 0.8 days and requires injections every 1 to 3 days to maintain stable serum levels [10]. It is rarely used as a primary TRT formulation today, though it appears in some compounded multi-ester blends.

The case for propionate over buccal testosterone is narrow. Some clinicians use short-acting esters to allow faster clearance if a complication arises (such as erythrocytosis or prostate symptoms), since testosterone levels fall within days rather than weeks. The buccal system offers similar flexibility: stopping application leads to serum testosterone declining to baseline within 24 to 48 hours, a clearance rate comparable to propionate and faster than cypionate or enanthate [1].

A 2020 review in Therapeutic Advances in Urology noted that propionate's injection frequency makes it poorly suited to long-term self-administration in most outpatient TRT programs, whereas mucosal and transdermal options are better matched to daily adherence patterns [10].

Testosterone Buccal vs. Testosterone Pellets

Subcutaneous testosterone pellets (brand name Testopel) are implanted in the hip or buttock area under local anesthesia every 3 to 6 months. Each pellet contains 75 mg of crystalline testosterone; most men receive 6 to 12 pellets per insertion, delivering 450 to 900 mg total per procedure [11].

The pellet's primary appeal is its long dosing interval. After insertion, serum testosterone rises over 1 to 2 weeks, stays relatively stable for 2 to 4 months, then declines. A 2019 study in The Aging Male (N=175) reported that pellets maintained serum testosterone above 400 ng/dL for an average of 5.3 months per insertion, with patient satisfaction ratings above 80% at 12 months [11].

Buccal testosterone offers a fundamentally different value proposition. It requires no office procedure, no incision, no anesthesia, and allows the patient to adjust or stop therapy with a single missed dose. Pellets cannot be retrieved once implanted; if side effects occur (such as a rapid rise in hematocrit), the only management option is watchful waiting while levels gradually decline. That irreversibility is the key risk to discuss with patients who have borderline cardiovascular or hematologic profiles.

Cost is another differentiator. Pellet insertion typically costs $400, $800 per procedure out of pocket when insurance does not cover it, while buccal tablets carry a per-dose cost without procedural fees.

Comparing Pharmacokinetics Across All Five Forms

The table below summarizes the key pharmacokinetic parameters for clinical decision-making.

| Formulation | Half-life | Dosing frequency | Peak:trough ratio | Reversibility | |---|---|---|---|---| | Buccal (Striant) | ~12 h (steady release) | Every 12 hours | Low | Within 24, 48 h | | Cypionate | ~8 days | Every 7 to 14 days | High | 3 to 5 weeks | | Enanthate | ~4.5 days | Every 5 to 7 days | Moderate-high | 2 to 3 weeks | | Propionate | ~0.8 days | Every 1 to 3 days | Moderate | 2 to 4 days | | Pellets (Testopel) | N/A (slow dissolution) | Every 3 to 6 months | Low | Not reversible |

Peak:trough ratio reflects the amplitude of serum testosterone fluctuation across a single dosing interval. Low ratios are generally associated with fewer mood and energy oscillations, though head-to-head symptom data comparing buccal with injectables in the same population remain limited [2, 8].

Who Is a Good Candidate for Buccal Testosterone?

The buccal route suits men who want needle-free TRT with rapid onset and rapid reversibility. Specific patient profiles that warrant a buccal option conversation include: men with needle phobia, men who cannot apply topical gels due to skin-transfer concerns (partners, children), men who travel frequently and prefer not to carry syringes through airport security, and men who require fast clearance due to borderline hematocrit or PSA.

Conversely, men with active periodontal disease, oral mucositis, or who use oral tobacco products are generally poor candidates, as gum health affects both tablet adhesion and local tolerability [1].

The Endocrine Society's 2018 guideline advises against testosterone therapy in men with a hematocrit above 54%, untreated severe obstructive sleep apnea, prostate cancer, a PSA above 4 ng/mL without urology evaluation, or a desire for fertility within 12 months [3]. Those contraindications apply regardless of formulation.

Monitoring Parameters During Buccal Testosterone Therapy

Monitoring on buccal testosterone follows the same schedule as any TRT protocol. The American Urological Association's 2018 guidelines recommend [4]:

• Total testosterone at 3 months after initiation (draw 4 to 12 hours after application for buccal)
• Hematocrit at 3 and 6 months, then annually
• PSA at 3 and 6 months, then annually in men over 40
• Digital rectal examination annually in men over 40
• Bone mineral density at 1 to 2 years if the indication included osteoporosis

Liver function tests are not routinely required for buccal or injectable formulations, unlike methyltestosterone (an oral 17-alpha-alkylated form no longer recommended) [3]. The buccal route does not involve hepatic first-pass, so the hepatotoxicity signal associated with oral anabolic steroids does not apply to Striant [1].

A fasting lipid panel at 6 to 12 months is reasonable given that testosterone therapy modestly reduces HDL cholesterol. A 2016 meta-analysis in BMJ Open (N=3,016) found mean HDL reductions of approximately 0.18 mmol/L across testosterone formulations [12]. That effect appears modest and clinically tolerable in most men without severe baseline dyslipidemia, though the prescribing physician should review the lipid panel in context.

Practical Tips for Improving Buccal Tablet Retention

Retention failure (tablet falling out) is the most common compliance problem with Striant. Strategies that may reduce this include:

Applying the tablet at the same times each day to build habit. Using a clean, dry finger for placement pressure. Avoiding sticky or hard foods for 30 minutes after application. Informing dental hygienists before cleanings so they can work around the tablet.

In the Dobs 2004 trial, approximately 7% of daily applications involved some displacement event, yet mean serum levels remained within normal range, suggesting partial absorption before displacement still delivers meaningful hormone exposure [2].

Interactions and Contraindications

Testosterone buccal carries the same drug interaction profile as all testosterone products. Concurrent anticoagulant therapy (particularly warfarin) may require INR monitoring, as androgens can potentiate anticoagulant effects [1]. Insulin-sensitizing effects of testosterone therapy may necessitate insulin or antidiabetic drug dose reductions in men with type 2 diabetes; a 2016 randomized trial in Diabetes Care (N=88) found that testosterone therapy reduced HbA1c by 0.87 percentage points versus placebo over 30 weeks [13].

Corticosteroids and adrenocorticotropic hormone (ACTH) used concurrently may increase fluid retention risk [1]. Men taking these agents should have blood pressure monitored more frequently during the first 3 months of testosterone therapy.

Starting Testosterone Buccal Through a Telehealth Provider

A telehealth-based TRT program for buccal testosterone follows the same clinical steps as in-person care. The prescribing physician reviews baseline labs (total testosterone, free testosterone, LH, FSH, SHBG, hematocrit, PSA, and comprehensive metabolic panel), confirms the diagnosis of hypogonadism per the Endocrine Society's threshold of morning total testosterone below 300 ng/dL on two separate measurements [3], writes a prescription for Striant 30 mg buccal tablets, and schedules a follow-up lab draw at 4 to 6 weeks.

The FDA requires that all testosterone prescriptions include a Medication Guide outlining risks including possible increased cardiovascular risk, polycythemia, and sleep apnea [6]. Patients should receive and acknowledge that guide before their first dose regardless of whether care is delivered in person or remotely.

A morning total testosterone below 300 ng/dL on two measurements taken at least one week apart remains the standard diagnostic threshold per the Endocrine Society 2018 guideline [3]. Symptom burden alone, without biochemical confirmation, is not a sufficient basis for initiating testosterone therapy under current guidelines.